FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF
申请人:Boatman P. Douglas
公开号:US20090258892A1
公开(公告)日:2009-10-15
The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor.
Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.
本发明涉及公式(Ia)的某些融合吡唑衍生物及其药学上可接受的盐,其具有有用的药理特性,例如作为RUP25受体激动剂。本发明还提供了包含该化合物的制药组合物,并且提供了使用该化合物和组合物治疗代谢相关疾病的方法,包括脂质代谢异常、动脉硬化、冠心病、胰岛素抵抗、2型糖尿病、X综合症等。此外,本发明还提供了将该化合物与其他活性剂(例如属于α-葡萄糖苷酶抑制剂、醛糖还原酶抑制剂、双胍类、HMG-CoA还原酶抑制剂、角鲨烷合成抑制剂、纤维酸类、LDL降解增强剂、血管紧张素转换酶(ACE)抑制剂、胰岛素分泌增强剂、DP受体拮抗剂等类别)组合使用的用途。